Emergent Inpatient Administration of Casirivimab and Imdevimab Antibody Cocktail for the Treatment of COVID-19 Pneumonia.
Emergent Inpatient Administration of Casirivimab and Imdevimab Antibody Cocktail for the Treatment of COVID-19 Pneumonia.
复制标题
Casirivimab和imdevimab抗体鸡尾酒的紧急住院治疗肺炎治疗。
DOI：
10.7759/cureus.15280
复制
发表时间：
2021-05-27
期刊：
影响因子：
--
通讯作者：
Neeki MM
中科院分区：
文献类型：
--
作者：
Phan AT;Gukasyan J;Arabian S;Wang S;Neeki MM
据了解，严重急性呼吸系统综合症冠状病毒 2 (SARS-CoV-2) 感染在老年人和已有疾病的人群中死亡率最高。病毒载量与住院患者死亡风险增加直接相关。一旦感染，大约 6 至 7 天后首先出现症状，随后在出现临床症状后 8-12 天出现免疫球蛋白 M (IgM) 抗体。最近的研究指出，casirivimab 和 imdevimab 的单克隆抗体组合 (REGN-COV2) 可有效降低感染的血清阴性非住院患者的病毒载量。然而，支持在住院环境中使用 REGN-COV2 的研究有限。我们介绍了一名 45 岁男性的病例，他确诊感染 SARS-CoV-2，并在一周内出现中度呼吸困难，症状逐渐恶化。该患者在入院时接受单次低剂量 REGN-COV2 输注治疗后，症状得到显着改善，随后出院，没有出现进一步的医疗并发症。
Infection by severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) is known to have the highest mortality rate among the elderly and those with pre-existing medical conditions. Viral load has been directly correlated with increased risk of mortality in hospitalized patients. Once infected, symptoms first arise approximately six to seven days later followed by immunoglobulin M (IgM) antibodies appearing 8-12 days after onset of clinical symptoms. Recent studies have noted that the monoclonal antibody combination of casirivimab and imdevimab (REGN-COV2) effectively reduces viral load in infected seronegative non-hospitalized patients. However, research supporting the use of REGN-COV2 in an inpatient setting is limited. We present the case of a 45-year-old male with confirmed SARS-CoV-2 infection with moderate dyspnea and progressive worsening of his symptoms over a week period. The patient showed drastic improvement of his symptoms after a single low-dose regimen of REGN-COV2 infusion while admitted to the hospital and was subsequently discharged without further medical complications.
登录
查看更多内容
在急诊室被诊断出的310名Covid-19患者的临床特征和呼吸支持：一项单中心回顾性研究。
影响因子：
4.6
作者：
Di Domenico SL;Coen D;Bergamaschi M;Albertini V;Ghezzi L;Cazzaniga MM;Tombini V;Colombo R;Capsoni N;Coen T;Cazzola KB;Di Fiore M;Angaroni L;Strozzi MA
通讯作者：
Strozzi MA
影响因子：
56.9
作者：
Baum, Alina;Fulton, Benjamin O.;Kyratsous, Christos A.
通讯作者：
Kyratsous, Christos A.
影响因子：
--
作者：
Deb P;Molla MMA;Saif-Ur-Rahman KM
通讯作者：
Saif-Ur-Rahman KM
DOI：
10.1056/nejmoa2108163
发表时间：
2021-12-02
期刊：
The New England journal of medicine
影响因子：
--
作者：
Weinreich DM;Sivapalasingam S;Norton T;Ali S;Gao H;Bhore R;Xiao J;Hooper AT;Hamilton JD;Musser BJ;Rofail D;Hussein M;Im J;Atmodjo DY;Perry C;Pan C;Mahmood A;Hosain R;Davis JD;Turner KC;Baum A;Kyratsous CA;Kim Y;Cook A;Kampman W;Roque-Guerrero L;Acloque G;Aazami H;Cannon K;Simón-Campos JA;Bocchini JA;Kowal B;DiCioccio AT;Soo Y;Geba GP;Stahl N;Lipsich L;Braunstein N;Herman G;Yancopoulos GD;Trial Investigators
通讯作者：
Trial Investigators
影响因子：
11.8
作者：
Magleby, Reed;Westblade, Lars F.;Satlin, Michael J.
通讯作者：
Satlin, Michael J.